Breast Cancer Clinical Trial
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
Summary
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
Eligibility Criteria
Inclusion Criteria:
Age >/= 18 years
Newly diagnosed histologically confirmed primary invasive breast carcinoma (Stage I-IV)
Pathologically confirmed HER2-positive breast cancer
Planned to receive trastuzumab-based therapy for a minimum of 12 months, or started trastuzumab-based therapy within the last weeks with a planned duration of at least 12 months.
Normal LV systolic function (EF greater than or equal to the institutional lower limit of normal)
William and able to comply with the requirements of the protocol
Exclusion Criteria:
Planned to receive an anthracycline-based regimen
Prior history of treatment with anthracycline chemotherapy
History of cardiovascular including cardiomyopathy, heart failure, or any other clinically significant cardiovascular disease (as determined by the investigator)
Uncontrolled hypertension, defined as systolic blood pressure >/= 160 mmHg and/or diastolic blood pressure >/= 90 mmHg (as determined by the investigator)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Hartford Connecticut, 06102, United States
Basking Ridge New Jersey, 07920, United States
Middletown New Jersey, 07748, United States
Montvale New Jersey, 07645, United States
Commack New York, 11725, United States
Harrison New York, 10604, United States
New York New York, 10065, United States
Rockville Centre New York, 11553, United States
How clear is this clinincal trial information?